IN THIS SECTION YOU WILL LEARN:
• FROM AUG. 1, 2013, TO JULY 31, 2014, THE FDA
APPROVED SIX NEW THERAPEUTICS FOR
TREATING CERTAIN TYPES OF CANCER.
• FIVE OF THE NEW ANTICANCER
THERAPEUTICS ARE MOLECULARLY
TARGETED, AND ONE OF THESE IS ALSO AN
• RESEARCH IS BEING PERFORMED TO HELP
CANCER SURVIVORS MEET THE NUMEROUS
CHALLENGES THEY FACE.
• CANCER GENOMICS RESEARCH IS A
FOUNDATION FOR NOVEL CLINICAL TRIALS
DESIGNED TO ACCELERATE THE PACE AT
WHICH NEW THERAPEUTICS ARE APPROVED
FOR PATIENT CARE.
• DURING THE SAME PERIOD, THE FDA
AUTHORIZED NEW USES FOR FIVE
PREVIOUSLY APPROVED ANTICANCER
THERAPEUTICS, TWO IMAGING AGENTS, AND
ONE SCREENING TEST.
Research has the power to transform and save lives.
Yesterday’s discoveries are being actively translated into
tomorrow’s breakthroughs, thanks to the dedicated e;orts
of researchers from across the entire biomedical research
community, as well as patients and their health care
providers. As a result, our journey toward the conquest of
cancer continues to advance at an ever-increasing pace.
;e cycle of biomedical research is fed by observations with the
potential to have an impact on the practice of medicine. ;ese
observations emanate from laboratory research, population
research, clinical practice, and clinical research including clinical
trials (see Figure 8, p. 33), and are made by investigators working
across the spectrum of research, from basic to population science
(see sidebar on Who We Are).